CJC-1295 began with a biotechnology challenge: how do you make a brief hormone signal last for days?

At ConjuChem in Montreal, Canada, Lucie Jetté, Roger Léger and colleagues engineered a longer-acting version of growth hormone-releasing hormone. Their 2005 paper described the molecule's development, giving it more than twenty years of published research history.

The key technology is called the drug affinity complex, or DAC. It allows the peptide to attach to albumin, a protein already circulating in the bloodstream. This molecular hitchhiking helps the signal remain in circulation much longer.

CJC-1295 stimulates receptors on the pituitary gland, encouraging the body to release growth hormone. Growth hormone then supports production of insulin-like growth factor one, an important signal involved in tissue growth and metabolism.

In two placebo-controlled trials published in 2006, Sam Teichman and colleagues studied healthy adults. After a single injection, average growth hormone levels rose for at least six days, while insulin-like growth factor one remained elevated for nine to eleven days.

Those findings demonstrated sustained hormone stimulation. They did not establish improvements in strength, recovery, fat loss or longevity.

Another important distinction: products called CJC-1295 without DAC are not the same long-acting molecule. Findings from the albumin-binding version cannot simply be transferred to them.

CJC-1295 remains an investigational peptide, without an FDA-approved use. Reported safety concerns include increased heart rate and reactions involving blood-vessel widening.

Its research story is one of molecular engineering: extending the lifetime of a biological message, and studying what that longer signal can achieve.

World Peptide Foundation. Peptides in 2. Every experience matters.